go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Ricesteele Manufacturing Ltd

Ricesteele Manufacturing Ltd
Unit 31, Cookstown Industrial Estate, Tallaght, Dublin 24,
Telephone: +353 1 451 0144
Fax: +353 1 452 1875
Summary of Product Characteristics last updated on medicines.ie: 24/01/2012
SPC Teedex Oral Solution

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 24/01/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   02-Dec-2011
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Section 6.5 Also includes: A 5ml dosing syringe with markings at both 2.5ml and 5ml is provided with the bottle.

Section 10: December 2011
Updated on 19/07/2011 and displayed until 24/01/2012
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   20-May-2011
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Section 2: Addition of Raspberry flavour contains Ethanol 1.3mg/5ml

Section 4.1: revised to:
Teedex Oral Solution is indicated in children aged over 2 years in the relief of teething pains, irritability associated with injections or feverishness, aches or pains, sleeplessness associated with the above conditions. Not recommended for routine use.

Section 4.2 revised to:
Children aged 2 to 6 years:  The usual dose is 5ml to 10ml three to four times daily.
Children over 6 years:  The usual dose is 10ml to 20ml three times daily or as directed by the physician.

Maximum of 4 doses per 24 hours.

Do not exceed the stated dose.

Carefully administer the correct volume to the child, using the measuring device provided, in order to minimise the risk of overdose.

Parents should consult a pharmacist or other healthcare professional before use in children under 6 years of age.

For short-term use only. Not recommended for routine use (See sections 4.4/4.1).

Teedex is contraindicated in children under 2 years (see section 4.3).

Teedex should be administered with caution to patients with known liver or renal impairment. (See section 4.4).

Section 4.3: Addition of the following points

This medicine should not be used in children with hypersensitivity to the active substance(s) or to any of the excipients.
 
This medicine should not be used in children who are taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment (See section 4.5).
This medicine should not be used in porphyric patients.

Section 4.4: Addition or revision of the following points.
1.                  For short-term use only (See section 4.2).
2.                 
Not recommended for routine use (see section 4.1/4.2)
3.                  Parents or carers should seek medical attention if the child’s condition fails to improve or deteriorates at any stage during  treatment.
4.         Contains Paracetamol. Do not take any other Paracetamol containing products.
5.                  Not more than 4 doses should be given in any 24 hours (see section 4.2)
6.                 
Parents or carers should ensure that no other antihistamine/diphenhydramine containing products are used concomitantly.
7.                  Parents or carers should consult a pharmacist or other healthcare professional before use in children under 6 years of age.
8.                  Keep out of sight and reach of children.
9.                 
Teedex should be administered with caution to patients with known liver or renal impairment. (See section 4.2).
10.                  This medicinal product contains small amounts of ethanol (alcohol), less than 100mg per 5ml dose.

Section 4.5 Addition of:
The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.

The rate of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by cholestyramine.

Chronic alcohol intake can increase the hepatotoxicity of paracetamol overdose. Acute alcohol intake may diminish an individual's ability to metabolise large doses of paracetamol, the plasma half-life of which can be prolonged.

The use of drugs that induce hepatic micosomal enzymes, such as anticonvulsants and oral contraceptives, may increase the extent of metabolism of paracetamol, resulting in reduced plasma concentrations of the drug and a faster elimination rate.

Diphenhydramine hydrochloride may enhance the sedative effects of CNS depressants including barbituates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics and alcohol.  It may also have an additive muscarinic action with other drugs such as atropine and some antidepressants. 

Diphenhydramine hydrochloride should not be used in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment as there is a risk of serotonin syndrome.

Deletion of: Effects of alcohol and other sedatives may be potentiated.

Section 4.8 Addition of :
Chronic hepatic necrosis has been reported in a patient who took daily therapeutic doses of paracetamol for about a year and liver damage has been reported after daily ingestion of excessive amounts for shorter periods.

A review of a group of patients with chronic active hepatitis failed to reveal differences in the abnormalities of liver function in those who were long-term users of paracetamol nor was the control of the disease improved after paracetamol withdrawal.

Nephrotoxic effects following therapeutic doses of paracetamol are uncommon. Papillary necrosis has been reported after prolonged administration.

Diphenhydramine Side Effects

Common side-effects: CNS effects: Drowsiness (usually diminishes within a few days), paradoxical stimulation, headache, psychomotor impairment.

Antimuscarinic effects: Urinary retention, dry mouth, blurred vision, gastrointestinal disturbances, thickened respiratory tract secretions.

Rare side-effects: Hypotension, extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, convulsions, palpitation, arrhythmia, hypersensitivity reactions, blood disorders and liver dysfunction.

Section 4.9 replace with

Liver damage is possible in adults who have taken 10g or more of paracetamol. Ingestion of 5g or more of paracetamol may lead to liver damage if the patient has risk factors, including the following ones:


Risk factors

a)      Long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John’s Wort or other drugs that induce liver enzymes, or
b)     
regular consumption of ethanol in excess of recommended amounts, or
c)     
likely glutathione depletion, e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms


Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria, and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.


Treatment

Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines.

Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with a liver unit.

Mild cases of overdose with antihistamines are mainly characterised by prominent anticholinergic effects including dry mouth, headache, nausea, tachycardia and urinary retention. Larger overdoses will have additional antihistamine effects which may depress or stimulate the CNS. In small children, the stimulatory effects predominate and clinical features include hallucinations, ataxia and convulsions. The child may be hot, flushed and have dilated pupils. Cardiorespiratory depression and coma can subsequently develop followed by rapid death. Overdosing diphenhydramine in adults usually results in drowsiness followed by convulsions and coma. Fever and flushing are uncommon.  Overdosed patients are best treated by gastric lavage and supportive measures. Administration of activated charcoal may be useful. Convulsions can be controlled with diazepam. Peripheral anticholinergic effects can be controlled with subcutaneous neostigmine. 

Section 10 revised to May 2011

Updated on 24/10/2008 and displayed until 19/07/2011
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   09/2008
Legal Category:   retail sale through pharmacy only

Free-text change information supplied by the pharmaceutical company

4.1       Therapeutic Indications

In the relief of teething pains, irritability associated with injections or feverishness, aches or pains, colds and flu, sleeplessness associated with the above conditions.

 

4.2       Posology and Method of Administration

   

Children aged 2 to 6 years: The usual dose is 5ml to 10ml (1-2 teaspoonsful) three to four times daily.

This product is no longer suitable for children under the age of two.

4.3       Contraindications

Addition of: This medicine should not be used in children under two years of age.

 

4.4       Special Warnings and Precautions for Use

Removal of point 5 Do not give to children under three months except on doctor's advice, and addition of 

            8.  Not more than 4 doses should be given in any 24 hours.

9. Patients should be instructed not to take any other cough and cold medicines with Teedex Oral Solution.

10.   Parents should consult a pharmacist or other healthcare professional before use in children under years of age.

 

10.       Date of (partial) revision of the text

            September 2008

Updated on 27/08/2008 and displayed until 24/10/2008
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 27/08/2008 and displayed until 27/08/2008
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   08/2008
Legal Category:   retail sale through pharmacy only

Free-text change information supplied by the pharmaceutical company

1.         TRADE NAME OF THE MEDICINAL PRODUCT

 

      Teedex Oral Solution

      Paracetamol 120mg/5ml

      Diphenhydramine Hydrochloride 12.5mg/5ml

 

 

2.         QUALITATIVE AND QUANTITATIVE COMPOSITION

 

Each 5ml contains: Paracetamol 120mg and Diphenhydramine hydrochloride 12.5mg.

 

            Excipients: Also contains:

            Propylene glycol 500mg/5ml

            Sorbitol liquid (non-crystallising) (E420) 1.5g/5ml

            Maltitol liquid (E965) 250mg/5ml

            Amaranth Red (E123) 180 micrograms/5ml

            E214 0.4mg/5ml

            E218 1.825mg/5ml

            and E216 0.275mg/5ml

 

            For a full list of excipients see section 6.1
 

9.          DATE OF FIRST AUTHORISATION/RENEWAL OF THE 

            AUTHORISATION

 

       Date of first authorisation: 01 April 1978

 

       Date of last renewal: 01 April 2008

 

 

10.       DATE OF REVISION OF THE TEXT

 

       August 2008

Updated on 17/08/2007 and displayed until 27/08/2008
Reasons for adding or updating:
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   04/2006
Legal Category:   retail sale through pharmacy only

Free-text change information supplied by the pharmaceutical company

Section 6.1 Replace sodium cyclamate with Neohesperidin Dihydrochalcone
 
Section 10 April 2006
Updated on 25/05/2005 and displayed until 17/08/2007
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 10 - Date of revision of the text
Updated on 22/07/2004 and displayed until 25/05/2005
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 6.1 - List of excipients
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
  • Correction of spelling/typing errors
Updated on 22/05/2003 and displayed until 22/07/2004
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Paracetamol
   Diphenhydramine Hydrochloride

Versions

 
24/01/2012 to Current
19/07/2011 to 24/01/2012
24/10/2008 to 19/07/2011
27/08/2008 to 24/10/2008
27/08/2008 to 27/08/2008
17/08/2007 to 27/08/2008
25/05/2005 to 17/08/2007
22/07/2004 to 25/05/2005
22/05/2003 to 22/07/2004
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo